Cipla expects to double sales of respiratory drugs by 2020

Cipla is building up its respiratory drug portfolio. Seroflo, a generic version of GSK Plc's inhaler Advair, is one of its biggest bets in that segment.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news